Loading clinical trials...
Loading clinical trials...
A Randomized, Partially-blinded, Single-dose, 4-way Cross-over Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Indacaterol Maleate Administered Via the Concept1 Device or Via the Simoon Device
Conditions
Interventions
Indacaterol 150 μg via the Concept1 dry-powder inhaler
Indacaterol 60 μg via the Simoon dry-powder inhaler
+2 more
Locations
4
Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Groningen, Netherlands
Novartis Investigative Site
Belfast, United Kingdom
Novartis Investigative Site
Manchester, United Kingdom
Start Date
October 1, 2009
Primary Completion Date
March 1, 2010
Completion Date
March 1, 2010
Last Updated
August 29, 2011
NCT07219173
NCT02327897
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions